Dr Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend
Dr. Lal PathLabs Ltd 路 Others (Uncategorized) 路 04 Nov 2026, 7:12 pm
Dr Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend Dr Lal PathLabs posted a strong Q2 FY27 performance for the quarter ended 30th Sep'26, with consolidated revenue rising 19.6% YoY to INR 8,739 mn and net profit growing 27.4% YoY to INR 1,939 mn. Basic EPS expanded to INR 11.51 from INR 9.03 YoY. The Board declared a second interim dividend of INR 5 per share (record date: 11th Nov'26) and approved an investment of up to INR 49.5 cr in its wholly owned subsidiary, Dr. Lal PathLabs FZCO, Dubai.
Original exchange filing (PDF)
More announcements from Dr. Lal PathLabs Ltd
- Attached 路 11 Nov 2026
- Attached 路 10 Nov 2026
- Attached 路 05 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates 路 04 Nov 2026
